Document is current
Any future updates will be listed below
-
Authors
Chikasawa, Yushi
Hagiwara, Takeshi
Bingo, Masato
Amano, Kagehiro
Kikuchi, Shigeru
Mitsuhashi, Ayano
Shinozawa, Keiko
Fukutake, Katsuyuki
Kinai, Ei
- License Information
-
More Information
Article History
Received: 4 February 2022
Revised: 20 April 2022
Accepted: 20 April 2022
First Online: 9 May 2022
Declarations
:
: YC has received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. TH has received research grant from Sanofi Genzyme, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. MB has received funding for research as a PI from Chugai Pharmaceuticals, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, and CSL-Behring. KA has received research grants from KM Biologics and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. KS was an endowed Assistant Professor funded by Baxter/Baxalta/Shire and CSL Behring until March 2020. KF has served as a paid consultant for KM Biologics, Chugai Pharmaceuticals and Sekisui Medical, and also honoraria from Bayer, Chugai Pharmaceuticals, Takeda Pharmaceutical, Pfizer, Fujimoto Pharmaceuticals, Sanofi Genzyme, SRL and Sekisui Medical. EK has received research grants from Chugai Pharmaceuticals and CSL-Behring, and also received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, and CSL-Behring.
